|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2011-2-25
|
|
pubmed:abstractText |
Romiplostim is a peptibody protein that augments thrombopoiesis by activating the thrombopoietin receptor.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright © 2010 American Cancer Society.
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
117
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
992-1000
|
|
pubmed:meshHeading |
pubmed-meshheading:20945323-Aged,
pubmed-meshheading:20945323-Aged, 80 and over,
pubmed-meshheading:20945323-Algorithms,
pubmed-meshheading:20945323-Disease Progression,
pubmed-meshheading:20945323-Drug Administration Schedule,
pubmed-meshheading:20945323-Female,
pubmed-meshheading:20945323-Humans,
pubmed-meshheading:20945323-Infusions, Intravenous,
pubmed-meshheading:20945323-Infusions, Subcutaneous,
pubmed-meshheading:20945323-Male,
pubmed-meshheading:20945323-Middle Aged,
pubmed-meshheading:20945323-Myelodysplastic Syndromes,
pubmed-meshheading:20945323-Neoplasm Staging,
pubmed-meshheading:20945323-Receptors, Fc,
pubmed-meshheading:20945323-Recombinant Fusion Proteins,
pubmed-meshheading:20945323-Risk Factors,
pubmed-meshheading:20945323-Thrombocytopenia,
pubmed-meshheading:20945323-Thrombopoietin,
pubmed-meshheading:20945323-Treatment Outcome
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes.
|
|
pubmed:affiliation |
Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio 44195, USA. sekerem@ccf.org
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Multicenter Study,
Clinical Trial, Phase II
|
